Reference
[1] January CT, Wann LS,
Calkins H, et al. 2019 Focused update on atrial fibrillation AHA/ACC/HRS
focused update of the 2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: a report of the American college of
cardiology/American heart association task force on clinical practice
guidelines and the heart rhythm society. Circulation 2019; 139:e125-51.
[2] Ansell J, Hirsh J, Hylek E, et al. American college of chest
physicians. Pharmacology and management of the vitamin K antagonists:
American college of chest physicians evidence-based clinical practice
guidelines (8th Edition). Chest 2008; 133:160S–98S.
[3] Boom MS, Berghuis EM, Nieuwkerk PT, et al. When do patients
prefer a direct oral anticoagulant over a vitamin K antagonist? Neth J
Med 2015; 73:368–72.
[4] Brekelmans MPA, Kappelhof M, Nieuwkerk PT, et al. Preference for
direct oral anticoagulants in patients treated with vitamin K
antagonists for venous thromboembolism. Neth J Med 2017; 75:50–5.
[5] SAVAYSA® [package insert], Basking Ridge, NJ: Daiichi
Sankyo, Inc.; 2020.
[6] Giugliano RP 1, Ruff CT, Braunwald E, et al. Edoxaban versus
warfarin in patients with atrial fibrillation. N Engl J Med 2013;
369:2093-104.
[7] Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple
Therapy in patients requiring oral anticoagulation after drug-eluting
stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;
65:1619-29.
[8] Hariharan S, Madabushi R. Clinical pharmacology basis of
deriving dosing recommendations for dabigatran in patients with severe
renal impairment. J Clin Pharmacol 2012; 52:119S-25S.
[9] Mikkelsen AP, Lindhardsen J, Lip GYH, et al. Female sex as a
risk factor for stroke in atrial fibrillation: a nationwide cohort
study. J Thromb Haemost 2012; 10:1745-51.
[10] Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK.
Edoxaban: a comprehensive review of the pharmacology and clinical data
for the management of atrial fibrillation and venous thromboembolism.
Cardiol Ther 2016; 5:1-18.
[11] Oh YB, Hong KS, Heo JH et al. New oral anticoagulants may be
particularly useful for Asian stroke patients. J Stroke 2014; 16:73-80.
[12] LIXIANA® [package insert], Seoul, Korea: Daiichi Sankyo
Korea Co., Ltd.; 2020.
[13] Schulman S, Kearon C. Subcommittee on control of
anticoagulation of the scientific and standardization committee of the
international society on thrombosis and haemostasis. definition of major
bleeding in clinical investigations of antihemostatic medicinal products
in non-surgical patients. J. Thromb Haemost 2005; 3:3692–4.
[14] Ayala C, Croft JB, Greenlund KJ, et al. Sex differences in US
mortality rates for stroke and stroke subtypes by race/ethnicity and
age, 1995-1998. Stroke 2002; 33:1197-201.
[15] Wang KL, Lip GY, Lin SJ, Chiang CE. Non-Vitamin K antagonist
oral anticoagulants for stroke prevention in Asian patients with
nonvalvular atrial fibrillation: meta-analysis. Stroke 2015; 46:2555-61.
[16] Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic
differences in the risk of intracranial hemorrhage among patients with
atrial fibrillation. J Am Coll Cardiol 2007; 50:309-15.
[17] Kang J, Park KW, Palmerini T, et al. Racial differences in
ischaemia/bleeding risk trade-off during anti-platelet therapy:
individual patient level landmark meta-analysis from seven RCTs. Thromb
Haemost 2019; 119:49-162.
[18] Yamashita T, Koretsune Y, Yasaka M, et al. Randomized,
multicenter, warfarin-controlled phase II study of edoxaban in Japanese
patients with non-valvular atrial fibrillation. Circ J 2012; 76:1840-7.
[19] Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous
thromboembolism and bleeding complications during anticoagulant
treatment in patients with cancer and venous thrombosis. Blood 2002;
100:3484-8.
[20] Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR.
Incidence of recurrent thromboembolic and bleeding complications among
patients with venous thromboembolism in relation to both malignancy and
achieved international normalized ratio: a retrospective analysis. J
Clin Oncol 2000; 18:3078-83.
[21] Johnstone C, Rich SE. Bleeding in cancer patients and its
treatment: a review. Ann Palliat Med 2018; 7:265-73.
Table 1. Factors associated with bleeding events caused by edoxaban use